<DOC>
	<DOC>NCT01994837</DOC>
	<brief_summary>A Phase 2, Open-Label, Multicenter study evaluating the preliminary efficacy and safety of ABT-199 administered orally in patients with AML.</brief_summary>
	<brief_title>A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>1. Histological or cytological confirmation of relapsed or refractory AML (by World Health Organization (WHO) classification) or untreated AML in patients who are unfit for intensive therapy. 2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2. 3. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance â‰¥ 50 mL/min; determined via urine collection for 24hour creatinine clearance or by the Cockcroft Gault formula using ideal body mass (IBM) instead of mass. 4. Subject must have adequate liver function. 1. Subject has received acute anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within 14 days or 5 halflives (whichever is shorter) prior to first dose of ABT199. 2. Subject has received a monoclonal antibody for antineoplastic intent within 8 weeks prior to the first dose of study drug. 3. Subject has received Potent CYP3A inducers (such as rifampin, carbamazepine, phenytoin and St. John's wort and Warfarin or requires the use of warfarin (due to potential drugdrug interactions that may potentially increase the exposure of warfarin and complications of this effect) within 7 days prior to the first dose of study drug. 4. Subject has received CYP3A inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within 5 days prior to the first dose of study drug. 5. Subject has a white blood cell count &gt; 25 x 10^9/L. 6. Subject has acute promyelocytic leukemia (FrenchAmericanBritish Class M3 AML). 7. Subjects with known active CNS disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>GDC-0199</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Myeloid Leukemia</keyword>
</DOC>